XML 108 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Jan. 31, 2022
USD ($)
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Dec. 31, 2022
USD ($)
Item
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Feb. 28, 2023
USD ($)
License And Collaboration Agreements [Line Items]                          
Revenue recognized related to upfront and milestone payments                 $ 1,369,000 $ 2,051,000      
Licenses revenue                 369,193,000 583,187,000 $ 614,060,000    
Deferred revenue                 15,346,000 16,709,000 18,632,000    
Product Revenue, Net                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 $ 366,511,000 580,320,000 $ 607,025,000    
Mochida Pharmaceutical Co., Ltd. | In-licenses                          
License And Collaboration Agreements [Line Items]                          
Milestones payment $ 1,000,000.0 $ 1,000,000.0                      
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                          
License And Collaboration Agreements [Line Items]                          
Upfront payment                       $ 2,700,000  
Edding | Out-licenses                          
License And Collaboration Agreements [Line Items]                          
Non-refundable up-front received               $ 15,000,000.0          
Number of indications of the regulatory milestone events relating to the submission and approval | Item                 3        
Amounts to be received upon achievement of the regulatory milestone events                 $ 33,000,000.0        
Sales-based milestone event payment                 120,000,000.0        
Revenue recognized related to upfront and milestone payments                 600,000 1,100,000      
Deferred revenue                 9,300,000 9,800,000      
Edding | Out-licenses | Licensing Revenue                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 7,700,000 7,100,000      
Edding | Out-licenses | Product Revenue, Net                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 200,000 300,000      
Edding | Out-licenses | Maximum                          
License And Collaboration Agreements [Line Items]                          
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                 153,000,000.0        
Amounts to be received upon achievement of the regulatory milestone events                 15,000,000.0        
Sales-based milestone event payment                 50,000,000.0        
Edding | Out-licenses | Minimum                          
License And Collaboration Agreements [Line Items]                          
Amounts to be received upon achievement of the regulatory milestone events                 2,000,000.0        
Sales-based milestone event payment                 5,000,000.0        
Edding | Out-licenses | Clinical Trial Application                          
License And Collaboration Agreements [Line Items]                          
Non-refundable milestone payment received             $ 1,000,000.0            
Biologix FZCo | Out-licenses                          
License And Collaboration Agreements [Line Items]                          
Revenue recognition period of non-refundable up-front payment             10 years            
Biologix FZCo | Out-licenses | Product Revenue, Net                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 1,000,000.0 1,400,000      
HLS | Out-licenses                          
License And Collaboration Agreements [Line Items]                          
Non-refundable up-front received           $ 5,000,000.0              
Non-refundable milestone payment received     $ 2,500,000 $ 3,800,000 $ 2,500,000                
Revenue recognized related to upfront and milestone payments                 700,000 900,000      
Deferred revenue                 5,600,000 6,200,000      
Non-refundable up-front received period           6 months              
Non-refundable milestone payment received           $ 3,800,000              
HLS | Out-licenses | Health Canada                          
License And Collaboration Agreements [Line Items]                          
Non-refundable milestone payment received           2,500,000              
HLS | Out-licenses | Licensing Revenue                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 8,200,000 7,500,000      
HLS | Out-licenses | Product Revenue, Net                          
License And Collaboration Agreements [Line Items]                          
Licenses revenue                 $ 2,900,000 $ 0      
HLS | Out-licenses | Maximum                          
License And Collaboration Agreements [Line Items]                          
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone           50,000,000.0              
HLS | Out-licenses | Achievement of REDUCE-IT Trial                          
License And Collaboration Agreements [Line Items]                          
Non-refundable milestone payment received           $ 2,500,000              
CSL Seqirus | Out-licenses | Subsequent Event                          
License And Collaboration Agreements [Line Items]                          
Upfront payment receivable                         $ 500,000
Event-related milestone payments receivable                         8,000,000.0
Additional product-related milestone payments receivable                         $ 4,000,000.0